All Things Urticaria – Learning about urticaria with Prof. Dr. Torsten Zuberbier
Episode 91 - EAACI 2024
25 Jun 2024
Professor Marcus Maurer and Professor Martin Metz reflect on the European Academy of Allergy and Clinical Immunology (EAACI) congress 2024, including novel treatments on the horizon, key takeaways and expectations for future meetings. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Additional resources for this episode: Remibrutinib demonstrates favourable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks; andEuropean Medicines Agency approved indications for omalizumab biosimilar. Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes! For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry. Episode 100 will be held live on UDAY (1 October 2024, 14:30 CEST). Submit your questions in advance to [email protected]. Follow UCARE on Instagram to be notified of more information https://www.instagram.com/ga2len_acare_ucare/.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
#2425 - Ethan Hawke
11 Dec 2025
The Joe Rogan Experience
SpaceX Said to Pursue 2026 IPO
10 Dec 2025
Bloomberg Tech
Don’t Call It a Comeback
10 Dec 2025
Motley Fool Money
Japan Claims AGI, Pentagon Adopts Gemini, and MIT Designs New Medicines
10 Dec 2025
The Daily AI Show
Eric Larsen on the emergence and potential of AI in healthcare
10 Dec 2025
McKinsey on Healthcare
What it will take for AI to scale (energy, compute, talent)
10 Dec 2025
Azeem Azhar's Exponential View